The Goldman Sachs Group Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price objective raised by stock analysts at The Goldman Sachs Group from $375.00 to $388.00 in a research note issued to investors on Friday,MarketScreener reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price objective indicates a potential upside of 21.32% from the company’s previous close.

Several other analysts have also recently issued reports on the company. Piper Sandler increased their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Sanford C. Bernstein boosted their price target on Insulet from $400.00 to $410.00 in a research note on Friday. Wolfe Research increased their price objective on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $370.00 price target on shares of Insulet in a report on Thursday. Finally, Leerink Partners boosted their price objective on shares of Insulet from $355.00 to $385.00 and gave the company an “outperform” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.38.

Insulet Trading Down 1.1%

Shares of PODD stock traded down $3.58 during trading hours on Friday, reaching $319.82. 677,166 shares of the stock were exchanged, compared to its average volume of 721,278. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet has a 12-month low of $230.05 and a 12-month high of $353.50. The firm has a market capitalization of $22.51 billion, a price-to-earnings ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company’s 50-day moving average price is $325.06 and its 200-day moving average price is $309.86.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts anticipate that Insulet will post 3.92 earnings per share for the current year.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Inspire Investing LLC boosted its stake in Insulet by 299.5% in the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 3,088 shares during the last quarter. Gradient Investments LLC acquired a new stake in Insulet in the 2nd quarter valued at $17,429,000. Goldman Sachs Group Inc. lifted its position in Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock worth $152,130,000 after acquiring an additional 10,628 shares in the last quarter. Vident Advisory LLC acquired a new position in Insulet in the 1st quarter worth $216,000. Finally, Mn Services Vermogensbeheer B.V. boosted its stake in shares of Insulet by 7.5% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 27,300 shares of the medical instruments supplier’s stock valued at $8,577,000 after buying an additional 1,900 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.